Diseases, Conditions, Syndromes

Researchers make discoveries to better understand SARS-CoV-2 virus

An effort led by Lin Li, Ph.D., assistant professor of physics at The University of Texas at El Paso, in collaboration with students and faculty from Howard University, has identified key variants that help explain the differences ...

Diseases, Conditions, Syndromes

How does SARS-CoV-2 evade our immune defenses?

How does SARS-CoV-2 evade our immune defenses? It's a good question, actually. When SARS-CoV-2 defeats host defenses, we need to know how it does so, and conversely, when host defenses prevail, that also needs to be understood. ...

Diseases, Conditions, Syndromes

Viral sequencing can reveal how SARS-CoV-2 spreads and evolves

The emergence of SARS-CoV-2 virus variants that are adding twists in the battle against COVID-19 highlight the need for better genomic monitoring of the virus, says Katia Koelle, associate professor of biology at Emory University.

Diseases, Conditions, Syndromes

Offer COVID-19 vaccines to pregnant or breastfeeding people

People who are pregnant, breastfeeding or trying to conceive should be offered the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine based on ethical grounds, argue authors of a commentary in CMAJ (Canadian ...

Medical research

Findings may help close door on COVID-19

Researchers at Vanderbilt University Medical Center (VUMC) and the University of Texas Medical Branch (UTMB) at Galveston have discovered what may be the Achilles' heel of the coronavirus, a finding that may help close the ...

Diseases, Conditions, Syndromes

Preclinical data on lead coronaviruses antibody

Adagio Therapeutics today published in vitro and in vivo data in Science on its lead antibody candidate, ADG2, which demonstrated similar or higher potency against SARS-CoV-2 compared to other monoclonal antibodies (mAbs) ...

Medications

Bamlanivimab plus etesevimab reduces SARS-CoV-2 viral load

(HealthDay)—Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in patients with mild-to-moderate ...

page 13 from 40